Damian Garde

New York

Reporter at Bloomberg News

@business reporter covering pharma / [email protected] / Signal/WhatsApp: 202-780-9154

Featured in: Favicon

statnews.com Favicon

businessinsider.com Favicon

foxnews.com Favicon

scribd.com Favicon

time.com

pbs.org

boston.com Favicon

scientificamerican.com Favicon

bostonglobe.com Favicon

theweek.com + 87 more

Articles

Cheaper Chinese HPV Vaccines Turn Merck’s Gardasil From Boom to Bust

1 day ago | msn.com | Damian Garde |Karoline Kan |Amber Tong

Continue reading More for You
Cheaper Chinese HPV Vaccines Turn Merck’s Gardasil From Boom to Bust

1 day ago | bloomberg.com | Damian Garde |Karoline Kan |Amber Tong

A Chinese woman receives the Gardasil 9 vaccination in 2018. (Bloomberg) -- Merck & Co. Chief Executive Officer Robert Davis was tired of talking about China. On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against cancer-causing HPV in China, which previously powered Merck’s growth. Finally, he had enough. “We need to get the China situation figured out,” he said.
Bristol Myers Schizophrenia Drug Cobenfy Failed in Key Study

1 day ago | bloomberg.com | Damian Garde

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Bristol Myers Squibb Co. agreed to buy radiological drug developer RayzeBio Inc. for about $4.1 billion, the latest deal in a buying spree to bolster its pipeline.
J&J’s earnings beat expectations as pharma girds for tariffs

1 week ago | crainsnewyork.com | Damian Garde

Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump moving decisively toward imposing tariffs on the pharmaceutical industry. The administration’s investigation into drug imports announced Monday, widely seen as a first step toward imposing levies on the industry, could actually be beneficial, J&J Chief Financial Officer Joe Wolk said in an interview.
J&J’s Earnings Beat as Pharma Girds for Looming US Tariffs (3)

1 week ago | news.bloombergtax.com | Damian Garde

Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump moving decisively toward imposing tariffs on the pharmaceutical industry. The administration’s investigation into drug imports announced Monday, widely seen as a first step toward imposing levies on the industry, could actually be beneficial, J&J Chief Financial Officer Joe Wolk said in an interview.
RFK Jr.’s Vaccine Panel Meets in Early Test for Scientific Sway

1 week ago | news.bloombergtax.com | Gerry Smith |Damian Garde

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
RFK Jr.’s Vaccine Panel Meets in Early Test for Scientific Sway

1 week ago | news.bloomberglaw.com | Gerry Smith |Damian Garde

A group of embattled government advisers will meet this week in the first major test of who controls US vaccine policy: scientific experts or Robert F. Kennedy Jr.The Advisory Committee on Immunization Practices gathers a few times a year to review data and make recommendations that determine when vaccines are given and whether they are covered by insurance. The influential group, mostly unknown outside of public health circles, normally does business with little fanfare. Robert F.
J&J mantiene estable sus perspectivas de ganancias mientras Trump se avecina con aranceles

1 week ago | bloomberglinea.com | Damian Garde

Bloomberg — Johnson & Johnson (JNJ) mantiene estables sus perspectivas de ganancias a pesar de que el presidente Donald Trump avanza decididamente hacia la imposición de aranceles a la industria farmacéutica. La investigación de la administración sobre las importaciones de medicamentos anunciada el lunes, ampliamente vista como un primer paso hacia la imposición de gravámenes a la industria, en realidad podría ser beneficiosa, dijo el CFO de J&J, Joe Wolk, en una entrevista.
RFK Jr.’s Vaccine Panel Meets in Early Test for Scientific Sway

1 week ago | bloomberg.com | Gerry Smith |Damian Garde

A group of embattled government advisers will meet this week in the first major test of who controls US vaccine policy: scientific experts or Robert F. Kennedy Jr.The Advisory Committee on Immunization Practices gathers a few times a year to review data and make recommendations that determine when vaccines are given and whether they are covered by insurance. The influential group, mostly unknown outside of public health circles, normally does business with little fanfare.
J&J’s Earnings Beat as Industry Girds for Looming Pharma Tariffs

1 week ago | dagenspharma.dk | Damian Garde

Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump moving decisively toward imposing tariffs on the pharmaceutical industry. The administration’s investigation into drug imports announced Monday, widely seen as a first step toward imposing levies on the industry, could actually be beneficial, J&J Chief Financial Officer Joe Wolk said in an interview.